References in periodicals archive ?
Release date- 02092019 - Leuven - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces that it will make a late breaking presentation covering the data from its positive Phase 1 clinical study with THR-149, a potent plasma kallikrein inhibitor, in patients with diabetic macular edema (DME) at the 19th European Society of Retina Specialists (EURETINA) 2019 Congress, which takes place from the 5-8 September in Paris, France.
Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following events in September 2019:
At 31 March 2019, it had interests in facilities in 38 states in the US; an estimated 35% common equity interest in Shurgard Self Storage SA (Euronext Brussels:SHUR) with facilities in seven western European nations; and an approximate 42% common equity interest in PS Business Parks Inc (NYSE:PSB).
Biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) disclosed on Monday the addition of Adrienne Graves, PhD to its board of directors.
Solvay SA (SOLB.BE) is listed on Euronext Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLB.BR) and in the United States its shares (SOLVY) are traded through a level-1 ADR program.
21 December 2017 - Belgium-based fruit and vegetables, flowers, plants and media provider Greenyard (Euronext Brussels: GREEN) is in advanced negotiations to acquire US-based Dole Food Company, Inc., the firm said.
The issue price is equal to the average closing price of TiGenix's share on Euronext Brussels over the 30-day period preceding the date on which the issuance of the new shares commenced (i.e., December 20, 2016) and represents a 23 percent premium over today's closing price on Euronext Brussels.
Amsterdam, Netherlands: ING will be included in the Bel 20 index, the leading share index of Euronext Brussels. The index includes the Brussels-listed shares with the highest market capitalisation provided they meet certain criteria.
By 1137 CET on Friday Fagron shares had lost 8.88% to EUR 25.12 on Euronext Brussels.
Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and NYSE Euronext Paris: CARD has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol.